Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study. (December 2016) - Tijeras-Raballand, A.; De Gramont, A.; Chiron, M.; Bachet, J.B.; André, T.; Auby, D.; Desramé, J.; Baba-Ahmed, N.; Lecaille, C.; Lebrun, V.; Louvet, C.; Tournigand, C.; et al.